Context Therapeutics Inc (CNTX) Stock Price, Quote & News

Company Profile

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 201...

Industry: Biotechnology

Sector: Healthcare

Phone: 267 225 7416

Website: www.contexttherapeutics.com

Address:

2001 Market Street, Suite 3915 Unit #15, Philadelphia, United States

LabPsycho Mar. 15 at 7:43 PM

$CNTX @J1476 @Doom_Gloom_AR Yes, CNTX surely weathered the (temporary?) storm the past couple weeks. I think $6 is a bit high - their market cap already pretty rich (compared to say CCCC which is at cash and in phase 2 and partnerships) IMO. Unless CTIM76 results are shockingly good. There probably is a reason I spent so much time, research and effort on this one over 2.5 yr ago doing molecular simulations and a video about Claudin 6 - it has a lot of appeal....but AMGN seemed to pause the development of thier Claudin 6 Bite for some reason. Good luck.

0 · Reply

topstockalerts Mar. 13 at 7:32 PM

$CNTX These lower liquidity setups often stay quiet until a headline sparks interest. Once volume appears the chart can move quickly.

0 · Reply

LabPsycho Mar. 13 at 7:08 PM

$CNTX Per @Doom_Gloom_AR post, I was in a rush and left out an important catalyst on my speculative future events below. * Phase 1a CTIM-76 data This could come after the IND filing. I also think these two potential announcements could be made only a few days apart. My way of looking at this, if there is a money raise before clinical data, yellow / red flag and retrace. If they wait and data is good and then raise, green flag going higher. All wild guesses of course. I am interested in reading other Posters ideas of what they think may transpire over the next several weeks

1 · Reply

LabPsycho Mar. 13 at 1:46 PM

$CNTX Here is my wild speculation of potential events before May 31, 2026 * CNTX to $3.50 near term * IND filing - share prices spike higher * Followed shortly thereafter by Private placement and share price drop * Several $$ MILLION payment to BCAB * Somehow I think there is a play / partnership / buyout something else going to happen between beat down BCAB and CNTX , but too complex even for me to speculate * Summer biotech blues - most biotechs getting stale. Wild speculations based on Stage 3 Wealth Transfer Iran war not further escalating.

3 · Reply

stck957 Mar. 13 at 12:59 PM

$CNTX If it can push through $3.30. Next targets would be. $3.50 $3.75 $4.00

1 · Reply

cyno Mar. 12 at 7:59 PM

$CNTX when is the earnings on this stock?

0 · Reply

J1476 Mar. 11 at 9:45 PM

$CNTX

0 · Reply

Doom_Gloom_AR Mar. 11 at 6:49 PM

$CNTX nice little talk at Leerink - TCE are hot - this will zoom to 1b company on decent results. https://event.summitcast.com/view/mT9poctHDNthc6b89WqVjf/XG5T44wDZtFqK3hid5hfLz

0 · Reply

hugoraciel Mar. 11 at 5:19 PM

$CNTX 5000 watchers n no one says anything on this play

0 · Reply

hugoraciel Mar. 9 at 10:21 PM

$CNTX and $ARDX ARE GETTING IN MY LAST NERV. takes weeks to move $1 Then 30 seconds to drop $2 Im exaggerating but its like

0 · Reply

Context Therapeutics to Participate in Upcoming Investor Conferences

Jan 16, 2026, 4:05 PM EST - 2 months ago

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 7, 2025, 7:30 AM EST - 4 months ago

Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting

Nov 5, 2025, 4:15 PM EST - 4 months ago

Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results

Oct 28, 2025, 8:00 AM EDT - 4 months ago

Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer

SKYE

Oct 6, 2025, 7:30 AM EDT - 5 months ago

Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 40th Annual Meeting

Oct 3, 2025, 4:15 PM EDT - 5 months ago

Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Aug 6, 2025, 4:11 PM EDT - 7 months ago

Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results

Jun 10, 2025, 7:10 AM EDT - 9 months ago

Context Therapeutics: Undervalued Cancer Fighter

Jun 2, 2025, 7:30 AM EDT - 10 months ago

Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting

May 29, 2025, 7:30 AM EDT - 10 months ago

Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer

May 7, 2025, 4:09 PM EDT - 11 months ago

Context Therapeutics Reports First Quarter 2025 Operating and Financial Results

May 5, 2025, 4:05 PM EDT - 11 months ago

Context Therapeutics Announces Chief Medical Officer Transition

Apr 30, 2025, 7:30 AM EDT - 11 months ago

Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting

Apr 9, 2025, 7:30 AM EDT - 1 year ago

Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95

Mar 26, 2025, 4:02 PM EDT - 1 year ago

Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025

Mar 20, 2025, 4:22 PM EDT - 1 year ago

Context Therapeutics Reports Full Year 2024 Operating and Financial Results

Jan 14, 2025, 4:58 PM EST - 1 year ago

Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76

Jan 13, 2025, 7:30 AM EST - 1 year ago

Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors

Nov 6, 2024, 4:06 PM EST - 1 year ago

Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results

Oct 23, 2024, 7:30 AM EDT - 1 year ago

Context Therapeutics to Participate in Upcoming Investor Conferences in November

Oct 16, 2024, 7:30 AM EDT - 1 year ago

Context Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Sep 4, 2024, 7:30 AM EDT - 1 year ago

Context Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of Directors

Aug 7, 2024, 4:17 PM EDT - 1 year ago

Context Therapeutics Reports Second Quarter 2024 Operating and Financial Results

Aug 1, 2024, 7:30 AM EDT - 1 year ago

Context Therapeutics Appoints Chief Medical Officer and Vice President of Clinical Operations

Jul 10, 2024, 2:06 PM EDT - 1 year ago

Context Therapeutics: Acquired Asset CT-95 Could Enhance T-Cell Engager Pipeline

Jul 10, 2024, 7:30 AM EDT - 1 year ago

Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95

May 8, 2024, 4:06 PM EDT - 2 years ago

Context Therapeutics Reports First Quarter 2024 Operating and Financial Results

May 2, 2024, 7:31 AM EDT - 2 years ago

Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76

Apr 1, 2024, 7:30 AM EDT - 2 years ago

Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers

Mar 21, 2024, 7:43 AM EDT - 2 years ago

Context Therapeutics Reports Full Year 2023 Operating and Financial Results

Nov 9, 2023, 4:15 PM EST - 2 years ago

Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results

Sep 27, 2023, 9:00 AM EDT - 2 years ago

Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Aug 9, 2023, 4:10 PM EDT - 2 years ago

Context Therapeutics Reports Second Quarter 2023 Operating and Financial Results

Aug 1, 2023, 7:30 AM EDT - 2 years ago

Context Therapeutics to Participate in Two August 2023 Investor Conferences

May 10, 2023, 4:39 PM EDT - 3 years ago

Context Therapeutics Reports First Quarter 2023 Operating and Financial Results

Apr 18, 2023, 10:15 AM EDT - 3 years ago

Significant Unmet Need In Solid Tumors Reported, And How Context Therapeutics (NASDAQ:CNTX) Plans To Make A Difference

Apr 3, 2023, 7:30 AM EDT - 3 years ago

Context Therapeutics to Participate in Two April 2023 Investor Conferences

Mar 22, 2023, 5:08 PM EDT - 3 years ago

Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates

Mar 15, 2023, 7:30 AM EDT - 3 years ago

Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023

Feb 6, 2023, 7:30 AM EST - 3 years ago

Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer

Jan 31, 2023, 7:30 AM EST - 3 years ago

Context Therapeutics' Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer

Jan 9, 2023, 7:30 AM EST - 3 years ago

Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers

Jan 4, 2023, 7:30 AM EST - 3 years ago

Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones

Dec 8, 2022, 7:30 AM EST - 3 years ago

Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer

Nov 29, 2022, 7:30 AM EST - 3 years ago

Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors

Nov 21, 2022, 9:11 AM EST - 3 years ago

Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer Symposium

Nov 9, 2022, 4:14 PM EST - 3 years ago

Context Therapeutics® Reports Third Quarter 2022 Operating and Financial Results

Oct 20, 2022, 7:30 AM EDT - 3 years ago

Context Therapeutics to Participate in the ThinkEquity Conference

Sep 27, 2022, 7:30 AM EDT - 3 years ago

Context Therapeutics® Amends Cash Guidance, Extends Runway into Q1 2024

LabPsycho Mar. 15 at 7:43 PM

0 · Reply

topstockalerts Mar. 13 at 7:32 PM

$CNTX These lower liquidity setups often stay quiet until a headline sparks interest. Once volume appears the chart can move quickly.

0 · Reply

LabPsycho Mar. 13 at 7:08 PM

1 · Reply

LabPsycho Mar. 13 at 1:46 PM

3 · Reply

stck957 Mar. 13 at 12:59 PM

$CNTX If it can push through $3.30. Next targets would be. $3.50 $3.75 $4.00

1 · Reply

cyno Mar. 12 at 7:59 PM

$CNTX when is the earnings on this stock?

0 · Reply

J1476 Mar. 11 at 9:45 PM

$CNTX

0 · Reply

Doom_Gloom_AR Mar. 11 at 6:49 PM

$CNTX nice little talk at Leerink - TCE are hot - this will zoom to 1b company on decent results. https://event.summitcast.com/view/mT9poctHDNthc6b89WqVjf/XG5T44wDZtFqK3hid5hfLz

0 · Reply

hugoraciel Mar. 11 at 5:19 PM

$CNTX 5000 watchers n no one says anything on this play

0 · Reply

hugoraciel Mar. 9 at 10:21 PM

$CNTX and $ARDX ARE GETTING IN MY LAST NERV. takes weeks to move $1 Then 30 seconds to drop $2 Im exaggerating but its like

0 · Reply

hugoraciel Mar. 9 at 9:22 PM

$CNTX Trend projection: CNTX is moving inside a rising channel. The upper trend-line extension points to $3.40–$3.70, with $3.42 sitting near the center of that path. Time estimate: about 3–4 weeks along the current trend slope.

0 · Reply

hugoraciel Mar. 9 at 9:02 PM

$CNTX there zero issues to sell

0 · Reply